Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy
about
Role of PD-1 in HIV pathogenesis and as target for therapyCytomegalovirus Infection May Contribute to the Reduced Immune Function, Growth, Development, and Health of HIV-Exposed, Uninfected African ChildrenGlucose Metabolism in T Cells and Monocytes: New Perspectives in HIV PathogenesisHuman Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease ProgressionFuture directions: lung aging, inflammation, and human immunodeficiency virusHIV and aging: emerging research issuesUnderstanding frailty, aging, and inflammation in HIV infectionIncomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV InfectionThe Sordid Affair Between Human Herpesvirus and HIVThe end of AIDS: HIV infection as a chronic diseaseRecent Insights into the HIV/AIDS Pandemic.Cytomegalovirus and HIV: A Dangerous Pas de DeuxImmunologic Biomarkers, Morbidity, and Mortality in Treated HIV InfectionDynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineSystemic effects of inflammation on health during chronic HIV infectionCoagulation and morbidity in treated HIV infection.Immune activation and HIV persistence: considerations for novel therapeutic interventions.Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.Residual immune dysregulation syndrome in treated HIV infection.Immunity to HIV in Early LifeHIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patientsA role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis.Can early therapy reduce inflammation?Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapyGut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Chronic HIV disease and activation of the coagulation systemImmune activation and HIV persistence: implications for curative approaches to HIV infection.Towards an HIV cure: a global scientific strategyThe use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation.HIV-associated chronic immune activation.The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trialPersistent immune activation in chronic HIV infection: do any interventions work?Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection.Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation.Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
P2860
Q24634293-3B800CE8-7DBB-4E88-8EF4-7FD6E9FAB15BQ26742161-EDDE31AC-DC83-41B6-AAAB-47B85BB87990Q26747110-87B970B7-7285-4014-9A39-5C3AC46B41D6Q26751304-AF1636A6-3BF5-4AEA-BA07-BD8C10D1BF34Q26996040-54836B92-D96E-4404-9F02-C837B227B5C4Q27016011-231D6794-4176-46AB-9148-FFAC3E864CF5Q27021143-E202E2FC-618F-485E-B131-C1C2EB4B5BBAQ27021524-9263779F-C059-4CFA-BA76-837E90E480B0Q27024262-544F4865-9809-4218-A545-D45EAF59E15CQ27687272-01BD89E6-4F70-49E0-BB25-8975571D896CQ28079533-884374F6-7037-42E4-AA8D-3529ECEC685BQ28083192-AD33C703-A166-4323-BE3D-D4B203667706Q28300749-2D65F253-5804-49D5-A2BC-094DCC0B8787Q30235024-303A6132-73EA-4A8C-8E74-A680CDFF3727Q30245376-E800A6D7-F883-45BB-9707-F872F2B1540FQ30245379-C2D06579-FA66-491C-97CC-F16E081B3A71Q31146636-B57E7BBE-59B3-44E1-945F-DAF336F9CB6AQ33577551-3D23C6BF-435F-4144-A33F-D0C9C5D2CD26Q33614424-DF2B3834-BA32-432C-A1DD-FF4722728ECCQ33698781-EB397C50-FC5F-4162-B877-0F1BFD6992E8Q33899641-1DD1BDFA-473F-46E5-92C7-444DAB8B984FQ33900251-F79FC5BE-B2B9-471C-A0D8-465C55DA06C8Q34020121-8F038EAC-E8F5-4BD6-84C2-E87E81EE03DDQ34033051-3A7A6ABC-7BBC-40B3-B9C9-B1E2890EC29FQ34134411-6EC85A98-F4AB-479F-9797-2A1EE52F574FQ34137496-CEA52CFD-0DE2-4601-9932-D2A5205141FEQ34159822-726F40DE-FB34-4FDC-813F-19194F13163CQ34206123-968D67B1-30EC-4825-B83B-3C3988B0291DQ34315572-5B2FA843-0434-4453-A9F7-58E8D75AE3CEQ34342368-B5440682-F396-4BDA-825E-E39B1DCCBBECQ34351320-8FE565C0-69BD-4915-90E0-A4B3AE574330Q34640562-68185AC9-3253-4425-B890-0F1558A674CCQ34652175-3C72A0DB-7570-438B-8B7E-6EAA75FC319EQ34653277-BBA1D60E-056D-4FF8-BC1C-B31681696C3EQ34818798-B236A432-8F07-42CA-9971-D118267BE973Q34851102-67D8C468-4B89-40AF-A2D7-1A01A275EC2DQ34943158-453E389D-B677-4DC2-97A1-7A8E442E5BC1Q35018886-3EB65DDF-D406-44A1-BCF0-469FF753F93BQ35043898-578FC2A7-5ACB-48D9-8BAD-2CB436B24419Q35109483-1287A640-52DD-445A-8E7B-38012A554530
P2860
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Valganciclovir reduces T cell ...... very on antiretroviral therapy
@en
Valganciclovir reduces T cell ...... very on antiretroviral therapy
@nl
type
label
Valganciclovir reduces T cell ...... very on antiretroviral therapy
@en
Valganciclovir reduces T cell ...... very on antiretroviral therapy
@nl
prefLabel
Valganciclovir reduces T cell ...... very on antiretroviral therapy
@en
Valganciclovir reduces T cell ...... very on antiretroviral therapy
@nl
P2093
P2860
P356
P1476
Valganciclovir reduces T cell ...... very on antiretroviral therapy
@en
P2093
Elizabeth Sinclair
Jeffrey N Martin
Juli Teague
Lawrence Corey
Lorrie Epling
Mark A Jacobson
Peter W Hunt
Russell P Tracy
P2860
P304
P356
10.1093/INFDIS/JIR060
P407
P577
2011-05-01T00:00:00Z